Literature DB >> 21368221

A two-step toward personalized therapies for prostate cancer.

Andrew S Goldstein1, Yang Zong, Owen N Witte.   

Abstract

Identifying the dominant genetic alterations that drive tumorigenesis is essential for developing targeted cancer therapies. Recent work has demonstrated that prostate tumors can be stratified by dominant genetic alterations, such as chromosomal rearrangements involving ETS (Erythroblastosis virus E26 transformation-specific) family transcription factors or overexpression of SPINK1, a gene that encodes a secreted serine protease inhibitor. In this issue of Science Translational Medicine, Ateeq et al. provide evidence to support a rationale for targeting the SPINK1 protein in the SPINK1+/ETS⁻ subset of prostate tumors and also describe a potential interaction of SPINK1 with epidermal growth factor receptor that could be an additional target for therapeutic intervention.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21368221      PMCID： PMC3089975          DOI： 10.1126/scitranslmed.3002169

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  27 in total

1.  Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.

Authors:  Bin Zhang; Adam C Strauss; Su Chu; Min Li; Yinwei Ho; Keh-Dong Shiang; David S Snyder; Claudia S Huettner; Leonard Shultz; Tessa Holyoake; Ravi Bhatia
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

2.  Integrative genomic profiling of human prostate cancer.

Authors:  Barry S Taylor; Nikolaus Schultz; Haley Hieronymus; Anuradha Gopalan; Yonghong Xiao; Brett S Carver; Vivek K Arora; Poorvi Kaushik; Ethan Cerami; Boris Reva; Yevgeniy Antipin; Nicholas Mitsiades; Thomas Landers; Igor Dolgalev; John E Major; Manda Wilson; Nicholas D Socci; Alex E Lash; Adriana Heguy; James A Eastham; Howard I Scher; Victor E Reuter; Peter T Scardino; Chris Sander; Charles L Sawyers; William L Gerald
Journal:  Cancer Cell       Date:  2010-06-24       Impact factor: 31.743

3.  Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib.

Authors:  Giuseppe Curigliano; Giuseppe Pelosi; Tommaso De Pas; Giuseppe Renne; Ottavio De Cobelli; Michela Manzotti; Gianluca Spitaleri; Filippo de Braud
Journal:  Prostate       Date:  2007-05-01       Impact factor: 4.104

4.  A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer.

Authors:  Eric J Small; Joseph Fontana; Nizar Tannir; Robert S DiPaola; George Wilding; Mark Rubin; Renee Bailey Iacona; Fairooz F Kabbinavar
Journal:  BJU Int       Date:  2007-10       Impact factor: 5.588

5.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.

Authors:  Mark E Davis; Jonathan E Zuckerman; Chung Hang J Choi; David Seligson; Anthony Tolcher; Christopher A Alabi; Yun Yen; Jeremy D Heidel; Antoni Ribas
Journal:  Nature       Date:  2010-03-21       Impact factor: 49.962

6.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Authors:  Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers
Journal:  Science       Date:  2009-04-09       Impact factor: 47.728

7.  Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer.

Authors:  Thorsten Schlomm; Patrick Kirstein; Liv Iwers; Birte Daniel; Thomas Steuber; Jochen Walz; Felix H K Chun; Alexander Haese; Jens Kollermann; Markus Graefen; Hartwig Huland; Guido Sauter; Ronald Simon; Andreas Erbersdobler
Journal:  Clin Cancer Res       Date:  2007-11-15       Impact factor: 12.531

8.  Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor.

Authors:  Nobuyuki Ozaki; Masaki Ohmuraya; Masahiko Hirota; Satoshi Ida; Jun Wang; Hiroshi Takamori; Shigeki Higashiyama; Hideo Baba; Ken-Ichi Yamamura
Journal:  Mol Cancer Res       Date:  2009-09-08       Impact factor: 5.852

9.  Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model.

Authors:  Carolyn Waugh Kinkade; Mireia Castillo-Martin; Anna Puzio-Kuter; Jun Yan; Thomas H Foster; Hui Gao; Yvonne Sun; Xuesong Ouyang; William L Gerald; Carlos Cordon-Cardo; Cory Abate-Shen
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

10.  High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer.

Authors:  A Gaber; M Johansson; U-H Stenman; K Hotakainen; F Pontén; B Glimelius; A Bjartell; K Jirström; H Birgisson
Journal:  Br J Cancer       Date:  2009-04-21       Impact factor: 7.640
View more
  5 in total

Review 1.  Cells of origin for cancer: an updated view from prostate cancer.

Authors:  L Xin
Journal:  Oncogene       Date:  2012-11-26       Impact factor: 9.867

Review 2.  Emerging biomarkers of prostate cancer (Review).

Authors:  Sarah K Martin; Taylor B Vaughan; Timothy Atkinson; Haining Zhu; Natasha Kyprianou
Journal:  Oncol Rep       Date:  2012-05-25       Impact factor: 3.906

3.  Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers.

Authors:  Christine Mehner; Ann L Oberg; Kimberly R Kalli; Aziza Nassar; Alexandra Hockla; Devon Pendlebury; Magdalena A Cichon; Krista M Goergen; Matthew J Maurer; Ellen L Goode; Gary L Keeney; Aminah Jatoi; Miklós Sahin-Tóth; John A Copland; Derek C Radisky; Evette S Radisky
Journal:  Oncotarget       Date:  2015-11-03

4.  Is There a Role for Genetic Information in Risk Assessment and Decision Making in Prostate Cancer?

Authors:  Mohamadreza Nowroozi; Mohsen Ayati; Erfan Amini; Reza Mahdian; Behzad Yousefi; Amir Arbab; Mansour Jamali Zawarei; Hasan Niroomand; Hamidreza Ghorbani; Alireza Ghadian
Journal:  Nephrourol Mon       Date:  2016-10-23

5.  Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-κB pathway in TMPRSS2/ERG fusion gene expressing prostate cancer.

Authors:  Longjiang Shao; Zhansong Zhou; Yi Cai; Patricia Castro; Olga Dakhov; Ping Shi; Yaoxia Bai; Huixiang Ji; Wenhao Shen; Jianghua Wang
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.